John M. Kane

83.0k total citations · 13 hit papers
928 papers, 52.6k citations indexed

About

John M. Kane is a scholar working on Psychiatry and Mental health, Clinical Psychology and Philosophy. According to data from OpenAlex, John M. Kane has authored 928 papers receiving a total of 52.6k indexed citations (citations by other indexed papers that have themselves been cited), including 610 papers in Psychiatry and Mental health, 141 papers in Clinical Psychology and 138 papers in Philosophy. Recurrent topics in John M. Kane's work include Schizophrenia research and treatment (565 papers), Bipolar Disorder and Treatment (194 papers) and Mental Health and Psychiatry (136 papers). John M. Kane is often cited by papers focused on Schizophrenia research and treatment (565 papers), Bipolar Disorder and Treatment (194 papers) and Mental Health and Psychiatry (136 papers). John M. Kane collaborates with scholars based in United States, Germany and United Kingdom. John M. Kane's co-authors include Christoph U. Correll, Stefan Leucht, Jeffrey A. Lieberman, Anil K. Malhotra, Delbert G. Robinson, Taishiro Kishimoto, Margaret G. Woerner, Todd Lencz, Stephen R. Marder and Werner Kissling and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

John M. Kane

901 papers receiving 50.4k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clozapine for the Treatment-Resistant Schizophrenic

1988 3.1k citations John M. Kane profile →
Remission in Schizophrenia: Proposed Criteria and Rationale for Consensus

2005 1.7k citations John M. Kane et al. American Journal of Psychiatry profile →
Schizophrenia

2015 775 citations René S. Kahn, Christoph U. Correll et al. profile →
Neuropsychology of First-Episode Schizophrenia: Initial Characterization and Clinical Correlates

2000 722 citations Delbert G. Robinson, John M. Kane et al. American Journal of Psychiatry profile →
Clinical implications of Brief Psychiatric Rating Scale scores

2005 683 citations Stefan Leucht, John M. Kane et al. profile →
Tardive Dyskinesia

1982 524 citations John M. Kane profile →
Objective User Engagement With Mental Health Apps: Systematic Search and Panel-Based Usage Analysis

2019 519 citations John M. Kane et al. Journal of Medical Internet Research profile →
Improving outcomes of first‐episode psychosis: an overview

2017 369 citations John M. Kane et al. profile →
Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies

2013 369 citations John M. Kane, Christoph U. Correll et al. profile →
The Use of Long-Acting Injectable Antipsychotics in Schizophrenia

2016 275 citations Christoph U. Correll, Leslie Citrome et al. The Journal of Clinical Psychiatry profile →
Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre–post studies

2021 209 citations John M. Kane, Christoph U. Correll et al. profile →
What is the risk‐benefit ratio of long‐term antipsychotic treatment in people with schizophrenia?

2018 201 citations Christoph U. Correll, José M. Rubio et al. profile →
The schizophrenia syndrome, circa 2024: What we know and how that informs its nature

2023 67 citations John M. Kane et al. Schizophrenia Research profile →

Peers

Countries citing papers authored by John M. Kane

Since Specialization

Citations

This map shows the geographic impact of John M. Kane's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John M. Kane with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John M. Kane more than expected).

Fields of papers citing papers by John M. Kane

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John M. Kane. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John M. Kane. The network helps show where John M. Kane may publish in the future.

Co-authorship network of co-authors of John M. Kane

This figure shows the co-authorship network connecting the top 25 collaborators of John M. Kane. A scholar is included among the top collaborators of John M. Kane based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John M. Kane. John M. Kane is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Benefits and risks of antipsychotic discontinuation in people with first and multi-episode psychotic disorders or with schizophrenia: why, when, how and in whom? 2025 ·Schizophrenia ·Christoph U. Correll, José M. Rubio, John M. Kane	0
2	The COMPASS scale for the assessment of individuals with first episode psychotic disorders 2024 ·Schizophrenia Research ·Delbert G. Robinson, Majnu John, Alexander L. Miller, Nina R. Schooler, John M. Kane	1
3	Multi-level barriers and facilitators to implementing evidence-based antipsychotics in the treatment of early-phase schizophrenia 2024 ·SHILAP Revista de lepidopterología ·Allison J. Carroll, Delbert G. Robinson, John M. Kane, (unknown), (unknown), Theresa L. Walunas, C. Hendricks Brown	2
4	TV-46000, A Long-Acting Subcutaneous Antipsychotic Agent, Demonstrated Improved Patient-Centered Outcomes in Patients with Schizophrenia 2024 ·Neuropsychiatric Disease and Treatment ·Leslie Citrome, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Marko A. Mychaskiw, John M. Kane	3
5	Assessing Health Technology Literacy and Attitudes of Patients in an Urban Outpatient Psychiatry Clinic: Cross-Sectional Survey Study 2024 ·JMIR Mental Health ·(unknown), (unknown), (unknown), (unknown), Anna Van Meter, Michael A. Kirschenbaum, Michael Sobolev, John M. Kane, Sunny X. Tang	6
6	Longitudinal study of inflammation and relapse in schizophrenia 2023 ·Schizophrenia Research ·Brian J. Miller, Henrique Lemos, Nina R. Schooler, Donald Goff, (unknown), John Lauriello, Theo C. Manschreck, Alan Mendelowitz, Del D. Miller, Joanne B. Severe, Daniel R. Wilson, Donna Ames, Juan Bustillo, John M. Kane, Mark Hyman Rapaport, P.F. Buckley	7
7	Olanzapine/Samidorphan in Young Adults With Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder Who Are Early in Their Illness 2023 ·The Journal of Clinical Psychiatry ·René S. Kahn, John M. Kane, Christoph U. Correll, (unknown), Adam Simmons, (unknown), (unknown), Beibei Hu, David McDonnell	12
8	103 Trends in Cannabis Use in New Jersey: Effects of COVID and Cannabis Legalization 2023 ·Annals of Emergency Medicine ·John M. Kane, Aaron D. Ames, Robin Patel, (unknown), (unknown), Rimma Perotte, (unknown)	0
9	The Effect of Longer Dosing Intervals for Long-Acting Injectable Antipsychotics on Outcomes in Schizophrenia 2023 ·Neuropsychiatric Disease and Treatment ·(unknown), Carmela Benson, (unknown), (unknown), Dean Najarian, (unknown), Steven Wang, Ute Richarz, Srihari Gopal, John M. Kane	20
10	Changes in Clinical Management of Patients with Schizophrenia Treated with Long-Acting Injectable Antipsychotics (LAIs), Including Telepsychiatry Use, During the COVID-19 Pandemic 2023 ·Neuropsychiatric Disease and Treatment ·Batool A Haider, Amy K. O’Sullivan, Leona Bessonova, (unknown), Eric D. Achtyes, Philip D. Harvey, John M. Kane, Stephen R. Saklad, (unknown), Amy Claxton, (unknown), (unknown), (unknown), Asia Sikora Kessler, Aaron Yarlas, Dawn I. Velligan	1
11	Cross-Platform Detection of Psychiatric Hospitalization via Social Media Data: Comparison Study 2022 ·JMIR Mental Health ·(unknown), (unknown), John M. Kane, Michael L. Birnbaum, Munmun De Choudhury	5
12	Relapse prevention through health technology program reduces hospitalization in schizophrenia 2022 ·Psychological Medicine ·Philipp Homan, Nina R. Schooler, Mary F. Brunette, Armando J. Rotondi, Dror Ben‐Zeev, Jennifer D. Gottlieb, Kim T. Mueser, Eric D. Achtyes, Susan Gingerich, Patricia Marcy, Piper Meyer-Kalos, Marta Hauser, Majnu John, Delbert G. Robinson, John M. Kane	9
13	A systematic review and pooled, patient‐level analysis of predictors of mortality in neuroleptic malignant syndrome 2021 ·Acta Psychiatrica Scandinavica ·Daniel Guinart, Fuminari Misawa, José M. Rubio, (unknown), Renato de Filippis, Chiara Gastaldon, John M. Kane, Christoph U. Correll	30
14	Examining Side Effect Variability of Antipsychotic Treatment in Schizophrenia Spectrum Disorders: A Meta-analysis of Variance 2021 ·Schizophrenia Bulletin ·(unknown), Stephanie Homan, Stefan Vetter, Erich Seifritz, John M. Kane, Maximilian Huhn, Stefan Leucht, Philipp Homan	8
15	Internet Search Activity of Young People With Mood Disorders Who Are Hospitalized for Suicidal Thoughts and Behaviors: Qualitative Study of Google Search Activity 2021 ·JMIR Mental Health ·(unknown), Anna Van Meter, Michael A. Kirschenbaum, (unknown), John M. Kane, Michael L. Birnbaum	8
16	The physical health and side-effect monitoring of patients prescribed clozapine: data from a clinical audit conducted in UK mental health services 2020 ·SHILAP Revista de lepidopterología ·Thomas R. E. Barnes, James H. MacCabe, John M. Kane, (unknown), Carol Paton	9
17	A Collaborative Approach to Identifying Social Media Markers of Schizophrenia by Employing Machine Learning and Clinical Appraisals 2017 ·Journal of Medical Internet Research ·Michael L. Birnbaum, Sindhu Kiranmai Ernala, Asra F. Rizvi, Munmun De Choudhury, John M. Kane	122
18	mHealth for Schizophrenia: Patient Engagement With a Mobile Phone Intervention Following Hospital Discharge 2016 ·JMIR Mental Health ·Dror Ben‐Zeev, Emily A. Scherer, Jennifer D. Gottlieb, Armando J. Rotondi, Mary F. Brunette, Eric D. Achtyes, Kim T. Mueser, Susan Gingerich, Christopher Brenner, Mark Begale, David C. Mohr, Nina R. Schooler, Patricia Marcy, Delbert G. Robinson, John M. Kane	99
19	Comparative Mortality Associated With Ziprasidone and Olanzapine in Real-World Use Among 18,154 Patients With Schizophrenia: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC) 2010 ·American Journal of Psychiatry ·Brian L. Strom, Sybil M. Eng, Gerald A. Faich, Robert F. Reynolds, Ralph B. D’Agostino, Jeremy N. Ruskin, John M. Kane	77
20	The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. 2003 ·PubMed ·John M. Kane, Stefan Leucht, Daniel Carpenter, John P. Docherty	121

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact